


## Cholest-5-ene-3 $\beta$ ,22(S)-diol

|                    |   |
|--------------------|---|
| Cat. No.:          | HY-137307   |
| CAS No.:           | 22348-64-7  |
| Molecular Formula: | C <sub>27</sub> H <sub>46</sub> O <sub>2</sub>  |
| Molecular Weight:  | 402.65  |
| Target:            | Others  |
| Pathway:           | Others  |
| Storage:           | Please store the product under the recommended conditions in the Certificate of Analysis. |



### BIOLOGICAL ACTIVITY

| <b>Description</b> | Cholest-5-ene-3 $\beta$ ,22(S)-diol ((22S)-Hydroxycholesterol) is an orally active oxysterol with no significant cytotoxic, oxidative, or inflammatory effects on human prokaryotic leukemia cells. Cholest-5-ene-3 $\beta$ ,22(S)-diol inhibits weight gain and increased serum triacylglycerol (TAG) levels in rat models <sup>[1][2]</sup> .  |                          |                      |                            |                      |                            |                                |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
|--------------------|--|--------------------------|----------------------|----------------------------|----------------------|----------------------------|--------------------------------|----------------------|--------------------------------|------|----|------|------|-----|-----|-----|-----|------|----|-----|---|------|-----|-----|-----|---------------|--|---------|--------------|-----------------|------------------------------------|---------|--|
| <b>In Vitro</b>    | Cholest-5-ene-3 $\beta$ ,22(S)-diol (10 $\mu$ g/mL, 20 $\mu$ g/mL; 24 h) shows no effect on phosphatidylserine externalization, mitochondrial transmembrane potential, cellular permeability to propidium iodide, and morphological nuclear changes in U937 cells <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only.  |                          |                      |                            |                      |                            |                                |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| <b>In Vivo</b>     | Cholest-5-ene-3 $\beta$ ,22(S)-diol (30 mg/kg; p.o.; added in diet, treated for 3 weeks) reduces body weight gain and abolishes high-fat diet-induced increase of triacylglycerol (TAG) levels in serum <sup>[2]</sup> .<br><br>Pharmacokinetic Analysis in Rats <sup>[2]</sup> <table border="1" data-bbox="345 1304 1515 1606"> <thead> <tr> <th>Route</th> <th>Dose (mg/kg)</th> <th>C<sub>max</sub> (ng/mL)</th> <th>T<sub>max</sub> (h)</th> <th>AUC<sub>t</sub> (ng·h/mL)</th> <th>AUC (ng·h/mL)</th> <th>T<sub>1/2</sub> (h)</th> <th>Extent of tritium exchange (%)</th> </tr> </thead> <tbody> <tr> <td>i.v.</td> <td>50</td> <td>22.4</td> <td>0.08</td> <td>174</td> <td>195</td> <td>8.1</td> <td>2.8</td> </tr> <tr> <td>p.o.</td> <td>50</td> <td>7.5</td> <td>4</td> <td>95.2</td> <td>104</td> <td>6.4</td> <td>1.2</td> </tr> </tbody> </table> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="345 1675 1515 1942"> <tr> <td>Animal Model:</td> <td>Male rats injected with Pentobarbital (20 mg, 50 mg/mL; i.p.)<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg/day</td> </tr> <tr> <td>Administration:</td> <td>Oral gavage; 3 weeks consecutively</td> </tr> <tr> <td>Result:</td> <td>Decreased body weight gain significantly after 1 week treatment.<br/>Increased gene expression of Ucp3 and Cpt2 in liver and skeletal muscle, and increased</td> </tr> </table> | Route                    | Dose (mg/kg)         | C <sub>max</sub> (ng/mL)   | T <sub>max</sub> (h) | AUC <sub>t</sub> (ng·h/mL) | AUC (ng·h/mL)                  | T <sub>1/2</sub> (h) | Extent of tritium exchange (%) | i.v. | 50 | 22.4 | 0.08 | 174 | 195 | 8.1 | 2.8 | p.o. | 50 | 7.5 | 4 | 95.2 | 104 | 6.4 | 1.2 | Animal Model: | Male rats injected with Pentobarbital (20 mg, 50 mg/mL; i.p.) <sup>[2]</sup> | Dosage: | 30 mg/kg/day | Administration: | Oral gavage; 3 weeks consecutively | Result: | Decreased body weight gain significantly after 1 week treatment.<br>Increased gene expression of Ucp3 and Cpt2 in liver and skeletal muscle, and increased |
| Route              | Dose (mg/kg)   | C <sub>max</sub> (ng/mL) | T <sub>max</sub> (h) | AUC <sub>t</sub> (ng·h/mL) | AUC (ng·h/mL)        | T <sub>1/2</sub> (h)       | Extent of tritium exchange (%) |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| i.v.               | 50   | 22.4                     | 0.08                 | 174                        | 195                  | 8.1                        | 2.8                            |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| p.o.               | 50   | 7.5                      | 4                    | 95.2                       | 104                  | 6.4                        | 1.2                            |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| Animal Model:      | Male rats injected with Pentobarbital (20 mg, 50 mg/mL; i.p.) <sup>[2]</sup>   |                          |                      |                            |                      |                            |                                |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| Dosage:            | 30 mg/kg/day   |                          |                      |                            |                      |                            |                                |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| Administration:    | Oral gavage; 3 weeks consecutively   |                          |                      |                            |                      |                            |                                |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |
| Result:            | Decreased body weight gain significantly after 1 week treatment.<br>Increased gene expression of Ucp3 and Cpt2 in liver and skeletal muscle, and increased   |                          |                      |                            |                      |                            |                                |                      |                                |      |    |      |      |     |     |     |     |      |    |     |   |      |     |     |     |               |  |         |              |                 |                                    |         |  |

---

protein level of Ucp3 in skeletal muscle after 3 weeks treatment.

---

## REFERENCES

---

- [1]. Lemaire-Ewing S, et al. Comparison of the cytotoxic, pro-oxidant and pro-inflammatory characteristics of different oxysterols. *Cell Biol Toxicol.* 2005 Mar;21(2):97-114.
- [2]. Tranheim Kase E, et al. Dietary supplementation with 22-S-hydroxycholesterol to rats reduces body weight gain and the accumulation of liver triacylglycerol. *Lipids.* 2012 May;47(5):483-93.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA